Clinical Trials
5 trialsNCT02954874 2026-06-03
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06195306 2026-05-20
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05941520 2026-05-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-05-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03317405 2026-05-04
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting